The coronary intravascular lithotripsy market is projected to be worth US$ 324.4 million in 2023. The market is expected to reach US$ 592.2 million by 2033, growing at a compound annual growth rate (CAGR) of 6.2%. the increase in cases of coronary artery disease. Intravascular lithotripsy (IVL) is becoming a more popular alternative to conventional athrectomy techniques such excisional, laser ablation, or rotational athrectomies.
Additionally, it has been said that IVL is simple to learn and can be a surgical procedure that is performed more frequently than alternative methods. The effectiveness of IVL and RA treatments on highly calcified coronary lesions was studied by the National Heart Centre Singapore (NHCS), and the results showed that IVL operations performed similarly to RA procedures in terms of angiographic success.
Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17677
The increasing incidence of coronary artery diseases has spurred the demand for advanced treatment options. Intravascular lithotripsy (IVL) has emerged as a promising alternative to traditional atherectomy treatments, such as excisional procedures, laser ablation, or rotational atherotomies.
What sets IVL apart is its ease of adoption, making it a preferred choice among medical professionals and patients alike. Research conducted by the National Heart Centre Singapore (NHCS) highlights the efficiency of IVL when compared to traditional rotational atherectomy (RA) procedures for severely calcified coronary lesions.
Key findings from the NHCS study reveal that IVL procedures deliver similar angiographic success rates to RA procedures, with the added benefit of requiring less fluoroscopy time. These outcomes underscore IVL as a safe and effective treatment option for patients with complex coronary artery diseases.
Key Takeaways :
1. Remarkable Market Growth: The IVL market is expected to experience significant growth, with a projected market value of US$ 592.2 million by 2033, representing a CAGR of 6.2% during this period. This growth is driven by the increasing incidence of coronary artery diseases and the growing popularity of IVL as a treatment option.
2. Rise of IVL as a Preferred Treatment: IVL has gained recognition as a viable alternative to traditional atherectomy treatments, including excisional procedures, laser ablation, and rotational atherotomies. Its ease of adoption, coupled with its efficacy, is making it a preferred choice among medical professionals and patients.
3. Efficiency of IVL: Research conducted by the National Heart Centre Singapore (NHCS) has shown that IVL procedures yield comparable angiographic success rates to traditional rotational atherectomy (RA) procedures for severely calcified coronary lesions. IVL also offers the advantage of requiring less fluoroscopy time, making it a more efficient and patient-friendly option.
4. Improved Patient Care: The adoption of IVL signifies a positive shift in the management of coronary artery diseases, offering improved cardiovascular care to patients. The technology’s effectiveness in treating complex coronary artery diseases is expected to lead to better patient outcomes and a higher quality of life.
5. Investment Opportunities: The growing IVL market presents attractive investment opportunities for healthcare providers, medical device companies, and investors looking to participate in the evolving landscape of coronary artery disease management. As the demand for IVL continues to rise, the market is poised for expansion.
6. Global Impact: The global adoption of IVL reflects a broader trend in healthcare toward innovative and minimally invasive treatment options. This technology has the potential to positively impact patients not only in developed regions but also in emerging markets, where the prevalence of coronary artery diseases is on the rise.
7. Continuous Advancements: Expect ongoing developments in IVL technology, further enhancing its efficacy and expanding its applications. These advancements are likely to drive continued growth in the IVL market and contribute to improved patient care.
8. Collaboration and Research: Collaboration between healthcare institutions, medical professionals, and medical device manufacturers will play a pivotal role in advancing IVL technology. Research efforts will continue to refine the procedure and provide evidence of its long-term benefits.
Key Players:
• Shockwave Medical, Inc.
Key Developments:On February 12, 2021, the USA FDA approved two Intravascular Lithotripsy (IVL) Systems- Shockwave Intravascular Lithotripsy (IVL) System and Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter, according to Shockwave Medical, Inc.
Coronary Intravascular Lithotripsy Market Segmentation:
By Distribution Channel:
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others
By Region:
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East & Africa
